Slips Technologies said today that it raised nearly $9 million for the super-slippery coating it’s developing, including a $3 million grant from a U.S. Energy Dept. agency. Named for its technology, “slippery liquid-infused porous surfaces,” the Cambridge, Mass.-based company’s coating is designed to create a self-healing liquid layer that’s too slippery for other fluids to adhere […]
Coatings
Johnson & Johnson Innovation backs 3D printing, coatings and contact lenses
Johnson & Johnson Innovation, the incubation arm of healthcare giant Johnson & Johnson (NYSE:JNJ), said today that it’s investing in a variety of medical device and pharmaceutical programs, including 3D printing, coatings and contact lenses. The new”investments and strategic transactions” feature a joint effort with MIT spinout Inkbit Corp., which is developing “a unique multi-material […]
Nanoscale features on implant surface reduce bacterial growth
Growing rates of implant infection and the increasing level of antibiotic-resistant bacteria have some surgeons nervous, and rightfully so – antibiotic-resistant bacteria can cause infections that are difficult and sometimes impossible to treat. “Antibiotic-resistant bacteria are being found in patients who have never taken antibiotics in the first place,” said Thomas Webster, professor & department chair […]
Teleflex wins another $2m from the Army for Semprus tech
Teleflex buys Semprus BioSciences in a deal worth up to $80 million
Sirona’s Q1 sales rise, earnings slide | Earnings Roundup
Sirona (NSDQ:SIRO) shares regained the 1.7% lost Friday after the dental devices maker reported a nearly 10% profit slide for its fiscal 2012 1st quarter.
The Long Island City, N.Y.-based firm reported profits of $38.3 million, or 67 cents per diluted share, on sales of $258.1 million during the 3 months ended Dec. 31, 2011.
That’s a top-line gain of 9.5% compared with profits of $42.4 million, or 75 cents diluted EPS, on sales of $235.6 million during Q1 2011.
MassDevice Podcast: Nano Surfaces CEO Joe Gatto
Coming generations of implanted medical devices will interact with the human body at the molecular level, using sophisticated nano-coatings to not only thwart microbial growth but to perform biological operations.
That’s the prediction of Nano Surfaces founder, president and CEO Joe Gatto. The Boston-based firm is developing technology it’s licensed from Cornell University to create self-assembling, anti-microbial coatings on a nanotech scale — and Gatto says that’s just the beginning. To prove it, he’s hitting to road to raise a Series A round from institutional investors.
MassDevice Podcast: Semprus BioSciences CEO David Lucchino
Medical device developers have long sought to reduce the risks involved with implants by applying coatings to prevent both bacteria and blood from sticking to the objects once they’re inside the body.
But coatings can wear off or otherwise lose their effectiveness. Semprus BioSciences Inc. is developing a solution to this fundamental limitation of implanted medical devices with its Sustain technology, which CEO David Lucchino describes as a “physical extension” of the device’s material.
Semprus steals Weaver from Boston Scientific
Semprus BioSciences Corp. appointed former Boston Scientific Corp. (NYSE:BSX) design engineer Douglas Weaver for a new executive role.
The Cambridge, Mass.-based firm named Weaver group leader of process development. He will head the company’s development of manufacturing processes and help the company scale up its vascular access products, Semprus said.
Semprus BioSciences taps pharma, MIT bigwigs for board
Semprus BioSciences Inc. tapped a veteran of the pharmaceutical world and a prominent MIT professor for its scientific advisory board.
Colin Gardner and Michael Cima will join the Cambridge, Mass.-based medical device coatings developer’s science panel effective immediately.
Gardner, a private industry consultant, put in time as chief scientific officer at TransForm Pharmaceuticals, which was acquired in 2005 by Johnson & Johnson (NYSE:JNJ). After the buyout he stayed on as senior vice president of research and site leader for TransForm. His resumé also includes a stint at Merck & Co. (NYSE:MRK).
Semprus taps new development VPs
Semprus BioSciences Corp. tapped a pair of executives to lead its business and product development operations.
The Cambridge, Mass.-based firm is developing a "dual-functional" vascular access catheter using its Semprus Surfaces covalent chemical bonding technique, "a permanent, non-leaching biomaterial modification to the device surface" according to the company’s website.
Semprus said it named Donald Anderson as its vice president of business development and Laurence Roth as VP of product development.
